2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert urologist Benjamin Lowentritt, MD, reviews trial data comparing PsA response achieved with apalutamide versus enzalutamide in patients with castration-sensitive prostate cancer.
Results and Conclusions